Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its growth in overseas revenue and the impact of currency depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink, established in 1998, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company's main business segments include formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the period from January to September 2025, Hepalink achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the Chinese yuan [3]. Market Activity - On February 25, Hepalink's stock rose by 0.74%, with a trading volume of 39.7381 million yuan and a turnover rate of 0.26%, leading to a total market capitalization of 17.945 billion yuan [1]. - The stock has seen a net outflow of 1.7001 million yuan from major investors, indicating a reduction in holdings over the past three days [4][5]. Technical Analysis - The average trading cost of Hepalink's shares is 11.67 yuan, with the stock currently near a support level of 12.23 yuan, suggesting potential for a rebound if this level holds [6].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization of Haiprui is 18.062 billion yuan, with a trading volume of 52.6162 million yuan on February 9 [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan in the last three years [8]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the eighth largest circulating shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization, aiming to provide high-quality and effective medications and services globally [2][3]. Group 1: Company Overview - Haiprui's main business segments include heparin sodium raw materials, downstream low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, Haiprui reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company has a total market capitalization of 17.901 billion yuan, with a trading volume of 51.35 million yuan and a turnover rate of 0.34% on February 4 [1]. Group 2: Financial Performance - The overseas revenue proportion for Haiprui is 93.04%, benefiting from the depreciation of the Renminbi [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Position and Trends - Haiprui is positioned within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is included in various concept boards such as the S&P Dow Jones China and FTSE Russell [7]. - The stock has shown a recent average trading cost of 11.66 yuan, with a current price near a resistance level of 12.37 yuan, indicating potential for upward movement if the resistance is broken [6].

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is experiencing a decline in stock price, attributed to various market factors, including its significant overseas revenue benefiting from the depreciation of the RMB [1][3]. Group 1: Company Overview - Shenzhen Hepalink was established in 1998 and operates as a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business segments include formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Group 2: Financial Performance - The company's overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Activity - On February 2, the company's stock price fell by 4.28%, with a trading volume of 80.1364 million yuan and a turnover rate of 0.53%, resulting in a total market capitalization of 17.373 billion yuan [1]. - The main capital inflow for the day was negative at 3.1333 million yuan, indicating a reduction in main capital positions over the past two days [4][5].

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares) [2]. - The main business segments include heparin sodium raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 18.048 billion yuan, with a trading volume of 87.8751 million yuan and a turnover rate of 0.57% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0093 million shares, an increase of 691,700 shares from the previous period [9]. Technical Analysis - The average trading cost of the stock is 11.62 yuan, with the current price approaching a resistance level of 12.37 yuan, indicating potential for upward movement if the resistance is broken [6].

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and strong overseas revenue [2][3]. Company Overview - Established in 1998 and listed in 2010, Hepalink's main business includes the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's revenue composition is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [7]. - As of September 30, 2025, Hepalink achieved a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company's overseas revenue accounts for 93.04%, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 17.079 billion yuan, with a trading volume of 31.2621 million yuan and a turnover rate of 0.22% [1]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Institutional Holdings - As of September 30, 2025, the eighth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 12.0093 million shares, an increase of 691,700 shares compared to the previous period [9]. Market Activity - The stock experienced a slight decline of 0.26% on December 17, with a net inflow of 429,600 yuan from major investors, representing 0.02% of the total [4][5].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization, aiming to provide high-quality and effective medications and services globally [2][3]. Group 1: Company Overview - Haiprui's main business segments include heparin raw materials, downstream low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin raw materials [7]. - As of September 30, 2025, Haiprui reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company has a total market capitalization of 17.123 billion yuan, with a trading volume of 33.7636 million yuan and a turnover rate of 0.23% on December 15 [1]. Group 2: Financial Performance - The overseas revenue contribution for Haiprui is 93.04%, benefiting from the depreciation of the Renminbi [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Position and Trends - Haiprui operates in the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including biopharmaceuticals, raw materials, vaccines, and innovative drugs [7]. - The stock has shown a net inflow of 605,300 yuan from major investors, indicating a lack of clear trend in major holdings, with the stock's average trading cost at 11.59 yuan [5][6].

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares), primarily engaged in the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to the parent company was 554 million yuan, a decrease of 29.04% year-on-year [7]. - As of September 30, 2025, the company had a total of 27,000 shareholders, an increase of 2.60% from the previous period [7]. Market Activity - On November 27, the company's stock price fell by 1.43%, with a trading volume of 35.8725 million yuan and a turnover rate of 0.24%, resulting in a total market capitalization of 17.153 billion yuan [1]. - The company has seen a net outflow of 2.5375 million yuan from major funds today, with a ranking of 79 out of 159 in its industry [4][5]. Dividend Information - Since its A-share listing, the company has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].

Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its growth in overseas revenue and the impact of currency depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business segments include: - Formulations: 63.06% - CDMO: 18.59% - Heparin sodium and low molecular weight heparin raw materials: 16.05% - Others: 2.30% [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the Renminbi [3]. Market Activity - On November 26, the stock price of Hepalink increased by 0.51%, with a trading volume of 36.7143 million yuan and a turnover rate of 0.25%, leading to a total market capitalization of 17.402 billion yuan [1]. - The stock has seen a net outflow of 223,600 yuan from major funds today, with a ranking of 74 out of 159 in its industry [4]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The eighth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 12.0093 million shares, an increase of 691,700 shares compared to the previous period [9]. Dividend Information - Since its A-share listing, Hepalink has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization, aiming to provide high-quality and effective medications and services globally [2][3]. Company Overview - Haiprui is headquartered in Shenzhen, China, and was listed on May 6, 2010. Its main business includes the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The revenue composition of Haiprui is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [7]. - As of September 30, 2025, Haiprui reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounts for 93.04%, benefiting from the depreciation of the RMB [3]. - Haiprui has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 25, Haiprui's stock rose by 0.77%, with a trading volume of 37.2831 million yuan and a turnover rate of 0.25%, bringing the total market capitalization to 17.314 billion yuan [1]. - The stock has seen a net outflow of 1.3632 million yuan from major investors today, with a ranking of 113 out of 159 in the industry [4]. Technical Analysis - The average trading cost of Haiprui's shares is 11.59 yuan, with the stock price approaching a resistance level of 11.81 yuan, indicating potential for a price correction if it fails to break through this level [6].